public health policy

The new pharma FDI policy undermines Indian generics, which may make drugs more expensive

By relaxing brownfield pharma FDI norms, the government is making way for multinational corporations to take over 'Make in India' generics companies.

The Union government’s decision to allow up to 74% foreign direct investment in pharmaceutical companies through the automatic route could threaten competition in the pharmaceutical sector and India’s role as a supplier of low cost, life-saving drugs across the developing world.

In 2013, the Department of Industrial Policy and Promotion, which is the nodal body for FDI policy in India, sought to restrict FDI in brownfield pharmaceutical projects (those in which a government or private entity buys or leases existing production facilities to start new production activity) to discourage multinational drug corporations from taking control of Indian generic companies that produced critical drugs and vaccines at prices lower than brand-name drugs. The decision to roll back on this policy now could mean that the majority stake in key generics manufacturers, like Cipla, can be easily transferred to multinational drug corporations.

Blow to world’s pharmacy

Cipla is a symbol across the world of all that India has achieved with its policy of self reliance in technology, domestic production and the provision of life-saving drugs to its people. It represents the aspirations of the country and its lawmakers who invested and built a generic industry to ensure that it had the technology to manufacture affordable essential medicines for its people.

Mahatma Gandhi with Cipla founder KA Hamied during his visit to Cipla in July 1939.
Mahatma Gandhi with Cipla founder KA Hamied during his visit to Cipla in July 1939.

Indians should be concerned about the recent decision to allow 74% brownfield FDI in pharma under the automatic route as this will speed up the ongoing pincer strategy to take over the pillars of the Indian generic industry, which is known as the pharmacy of the developing world. Companies like Cipla that contributed not only to employment, development of indigenous technologies and innovation but also significantly to the availability of medicines to tackle public health challenges, could be taken over with no prior approval.

Generic companies like Cipla are now at great risk of being merged and acquired, becoming a part of multinational pharmaceutical corporations like Pfizer, GlaxoSmithKline, Merck or Bristol-Myers Squibb. They might no longer play a role in meeting the public health needs of the developing world, but simply be cogs of the multinational pharmaceutical industry whose sole aim seems to be to generate supra-normal profits for its CEOs and shareholders.

Affordable healthcare hit

It is important to distinguish between brownfield investments that are basically mergers and acquisitions, and greenfield investments in which the parent company builds the business up from scratch. Greenfield FDI in the pharma sector will have a stronger and long-term impact on growth as foreign investors will have to build new manufacturing units and/or research and development facilities from the ground up, contributing to jobs and technology transfer to the country.

Unfortunately, government policies over the last decade have increasingly encouraged brownfield investments, which work like this: A Japanese or US pharmaceutical corporation purchases a Indian generic company, resulting in a transfer of the controlling stake, with huge profits accruing to the firm’s previous owners without resulting in major investment in the country.

Ranbaxy is a classic example. In 2008, the owners of the company, the Singh brothers, sold their stake in the company, which consisted of brands, production units and research and development facilities. The owners earned huge profits, but the company itself has all but disappeared. Ranbaxy’s phenomenal growth stagnated after it was acquired by the Japanese company Daiichi, and it was finally resold to Sun Pharma in India, which was one of its competitors. From one of the leading generic manufacturers that took pride in leading the production and supply of affordable HIV and cancer medicines like Zidovudine and Imatinib at the beginning of the century, Ranbaxy today exists only as a subsidiary for Sun Pharma’s branded business.

Relaxing the norms on brownfield FDI in pharma will not contribute to technology transfer or new research and development facilities. It will only allow capital flow from India to developed countries whose pharmaceutical industry is taking over key Indian companies to enter the generic branded business in high and middle income countries. In the process, India will lose an independent generic industry that fiercely competes with patent-holding multinational pharmaceutical corporations to bring low cost essential medicines to the market.

Leena Menghaney is a lawyer working on access to medicines in developing countries.

We welcome your comments at letters@scroll.in.
Sponsored Content  BY 

In a first, some of the finest Indian theatre can now be seen on your screen

A new cinematic production brings to life thought-provoking plays as digital video.

Though we are a country besotted with cinema, theatre remains an original source of provocative stories, great actors, and the many deeply rooted traditions of the dramatic arts across India. CinePlay is a new, ambitious experiment to bring the two forms together.

These plays, ‘filmed’ as digital video, span classic drama genre as well as more experimental dark comedy and are available on Hotstar premium, as part of Hotstar’s Originals bouquet. “We love breaking norms. And CinePlay is an example of us serving our consumer’s multi-dimensional personality and trusting them to enjoy better stories, those that not only entertain but also tease the mind”, says Ajit Mohan, CEO, Hotstar.

The first collection of CinePlays feature stories from leading playwrights, like Vijay Tendulkar, Mahesh Dattani, Badal Sircar amongst others and directed by film directors like Santosh Sivan and Nagesh Kukunoor. They also star some of the most prolific names of the film and theatre world like Nandita Das, Shreyas Talpade, Saurabh Shukla, Mohan Agashe and Lillete Dubey.

The idea was conceptualised by Subodh Maskara and Nandita Das, the actor and director who had early experience with street theatre. “The conversation began with Subodh and me thinking how can we make theatre accessible to a lot more people” says Nandita Das. The philosophy is that ‘filmed’ theatre is a new form, not a replacement, and has the potential to reach millions instead of thousands of people. Hotstar takes the reach of these plays to theatre lovers across the country and also to newer audiences who may never have had access to quality theatre.

“CinePlay is merging the language of theatre and the language of cinema to create a third unique language” says Subodh. The technique for ‘filming’ plays has evolved after many iterations. Each play is shot over several days in a studio with multiple takes, and many angles just like cinema. Cinematic techniques such as light and sound effects are also used to enhance the drama. Since it combines the intimacy of theatre with the format of cinema, actors and directors have also had to adapt. “It was quite intimidating. Suddenly you have to take something that already exists, put some more creativity into it, some more of your own style, your own vision and not lose the essence” says Ritesh Menon who directed ‘Between the Lines’. Written by Nandita Das, the play is set in contemporary urban India with a lawyer couple as its protagonists. The couple ends up arguing on opposite sides of a criminal trial and the play delves into the tension it brings to their personal and professional lives.

Play

The actors too adapted their performance from the demands of the theatre to the requirements of a studio. While in the theatre, performers have to project their voice to reach a thousand odd members in the live audience, they now had the flexibility of being more understated. Namit Das, a popular television actor, who acts in the CinePlay ‘Bombay Talkies’ says, “It’s actually a film but yet we keep the characteristics of the play alive. For the camera, I can say, I need to tone down a lot.” Vickram Kapadia’s ‘Bombay Talkies’ takes the audience on a roller coaster ride of emotions as seven personal stories unravel through powerful monologues, touching poignant themes such as child abuse, ridicule from a spouse, sacrifice, disillusionment and regret.

The new format also brought many new opportunities. In the play “Sometimes”, a dark comedy about three stressful days in a young urban professional’s life, the entire stage was designed to resemble a clock. The director Akarsh Khurana, was able to effectively recreate the same effect with light and sound design, and enhance it for on-screen viewers. In another comedy “The Job”, presented earlier in theatre as “The Interview”, viewers get to intimately observe, as the camera zooms in, the sinister expressions of the interviewers of a young man interviewing for a coveted job.

Besides the advantages of cinematic techniques, many of the artists also believe it will add to the longevity of plays and breathe new life into theatre as a medium. Adhir Bhat, the writer of ‘Sometimes’ says, “You make something and do a certain amount of shows and after that it phases out, but with this it can remain there.”

This should be welcome news, even for traditionalists, because unlike mainstream media, theatre speaks in and for alternative voices. Many of the plays in the collection are by Vijay Tendulkar, the man whose ability to speak truth to power and society is something a whole generation of Indians have not had a chance to experience. That alone should be reason enough to cheer for the whole project.

Play

Hotstar, India’s largest premium streaming platform, stands out with its Originals bouquet bringing completely new formats and stories, such as these plays, to its viewers. Twenty timeless stories from theatre will be available to its subscribers. Five CinePlays, “Between the lines”, “The Job”, “Sometimes”, “Bombay Talkies” and “Typecast”, are already available and a new one will release every week starting March. To watch these on Hotstar Premium, click here.

This article was produced on behalf of Hotstar by the Scroll.in marketing team and not by the Scroll.in editorial staff.